Title : Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.

Pub. Date : 2018 May

PMID : 29605737






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 On December 2016, it was granted accelerated approval by the FDA, based on data from two multicenter, single arm, phase II trials that evaluated the efficacy of Rucaparib in patients with deleterious, germline and/or somatic BRCA mutation-associated, advanced OC, who have been treated with two or more lines of chemotherapy. rucaparib BRCA1 DNA repair associated Homo sapiens